Carolyn F. Deacon

Carolyn F. Deacon

Associate Professor


  1. Published

    Immunoassays for the incretin hormones GIP and GLP-1

    Deacon, Carolyn F. & Holst, Jens Juul, 2009, In: Best Practice & Research: Clinical Endocrinology & Metabolism. 23, 4, p. 425-32 7 p.

    Research output: Contribution to journalJournal articlepeer-review

  2. Published

    Dipeptidyl peptidase 4 inhibition with sitagliptin: a new therapy for type 2 diabetes.

    Deacon, Carolyn F., 2007, In: Expert Opinion on Investigational Drugs. 16, 4, p. 533-45 12 p.

    Research output: Contribution to journalJournal articlepeer-review

  3. Published

    Linagliptin, a xanthine-based dipeptidyl peptidase-4 inhibitor with an unusual profile for the treatment of type 2 diabetes

    Deacon, Carolyn F. & Holst, Jens Juul, Jan 2010, In: Expert Opinion on Investigational Drugs. 19, 1, p. 133-40 8 p.

    Research output: Contribution to journalJournal articlepeer-review

  4. Published

    Degradation of endogenous and exogenous gastric inhibitory polypeptide in healthy and in type 2 diabetic subjects as revealed using a new assay for the intact peptide

    Deacon, Carolyn F., Nauck, M. A., Meier, J., Hücking, K. & Holst, Jens Juul, 2000, In: Journal of Clinical Endocrinology and Metabolism. 85, p. 3575-3581

    Research output: Contribution to journalJournal articlepeer-review

  5. Published

    Degradation of glucagon-like peptide-1 in vitro yields an N-terminally truncated peptide which is a major endogenous metabolite in vivo.

    Deacon, Carolyn F., Johnsen, A. H. & Holst, Jens Juul, 1995, In: Journal of Clinical Endocrinology and Metabolism. 80, p. 952-957

    Research output: Contribution to journalJournal articlepeer-review

  6. Published

    Dipeptidyl peptidase IV resistant analogues of glucagon-like peptide-1 which have extended metabolic stability and improved biological activity

    Deacon, Carolyn F., Knudsen, L. B., Madsen, K., Wiberg, F. C., Jacobsen, O. & Holst, Jens Juul, 1998, In: Diabetologia. 41, p. 271-278

    Research output: Contribution to journalJournal articlepeer-review

  7. Published

    Both subcutaneously and intravenously administered glucagon-like peptide-1 are rapidly degraded from the amino terminus in type II diabetic patients and in healthy subjects.

    Deacon, Carolyn F., Nauck, M. A., Nielsen, M. T., Pridal, L. & Holst, Jens Juul, 1995, In: Diabetes. 44, p. 1126-1131

    Research output: Contribution to journalJournal articlepeer-review

  8. Published

    Dipeptidyl peptidase IV inhibition reduces the degradation and clearance of GIP and potentiates its insulinotropic and antihyperglycemic effects in anesthetized pigs

    Deacon, Carolyn F., Danielsen, P., Klarskov, L., Holst, Jens Juul & Olesen, M., 2001, In: Diabetes. 50, p. 1588-1597

    Research output: Contribution to journalJournal articlepeer-review

  9. Published

    Dipeptidyl peptidase IV inhibition potentiates the insulinotropic effect of glucagon-like peptide 1 in the anesthetized pig.

    Deacon, Carolyn F., Hughes, T. E. & Holst, Jens Juul, 1998, In: Diabetes. 47, p. 764-769

    Research output: Contribution to journalJournal articlepeer-review

  10. Published

    Glucagon-like peptide-1: A basis for new approaches to the management of Diabetes

    Deacon, Carolyn F., Holst, Jens Juul & Carr, R. D., 1999, In: Drugs of Today. 35, p. 159-170

    Research output: Contribution to journalJournal articlepeer-review

ID: 9220